NL-OMON50487招募中4 期
Investigating the occurrence of everolimus long-term side effects by follow up of everolimus trough blood concentrations. - Everolimus TDM to predict long-term toxicity
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Patients currently treated with everolimus for any type of cancer, such as the
- •EMA registered indications i.e. advanced (Hormone-Receptor [HR]-positive,
- •HER2-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or
- •neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin.
- •-Aged 18 or above
- •-Able and willing to sign the informed consent
排除标准
- •-No informed consent
- •-Alactasia
- •-Lenvatinib combination therapy with everolimus (mRCC)
研究者
相似试验
进行中（未招募）
1 期
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
已完成
2 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.polycystic liver disease10019654NL-OMON32654niversitair Medisch Centrum Sint Radboud44
进行中（未招募）
1 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver diseaseEUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44
招募中
不适用
Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion Subsets (OCT and IVUS sub analysis)Complex coronary artery diseaseJPRN-UMIN000021122The PCI Guideline Research Society50
尚未招募
不适用
Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion SubsetsJPRN-UMIN000008651The PCI Guideline Research Society800